Title |
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
|
---|---|
Published in |
Genome Biology, September 2016
|
DOI | 10.1186/s13059-016-1050-9 |
Pubmed ID | |
Authors |
Paul Geeleher, Nancy J. Cox, R. Stephanie Huang |
Abstract |
We show that variability in general levels of drug sensitivity in pre-clinical cancer models confounds biomarker discovery. However, using a very large panel of cell lines, each treated with many drugs, we could estimate a general level of sensitivity to all drugs in each cell line. By conditioning on this variable, biomarkers were identified that were more likely to be effective in clinical trials than those identified using a conventional uncorrected approach. We find that differences in general levels of drug sensitivity are driven by biologically relevant processes. We developed a gene expression based method that can be used to correct for this confounder in future studies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 4 | 36% |
Italy | 1 | 9% |
United States | 1 | 9% |
Ireland | 1 | 9% |
Greece | 1 | 9% |
Unknown | 3 | 27% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 5 | 45% |
Members of the public | 5 | 45% |
Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 67 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 23 | 34% |
Researcher | 15 | 22% |
Student > Master | 6 | 9% |
Student > Bachelor | 3 | 4% |
Student > Postgraduate | 3 | 4% |
Other | 5 | 7% |
Unknown | 12 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 18 | 27% |
Biochemistry, Genetics and Molecular Biology | 16 | 24% |
Computer Science | 9 | 13% |
Medicine and Dentistry | 5 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Other | 4 | 6% |
Unknown | 13 | 19% |